To assess additional evidence for the complementarity of HE4, HE4 Ag-AAb, and OPN to CA125 in a multi-marker panel, random forest Classifiers were developed on the training set using either all four markers or CA125 alone to separate ovarian cancer patients from benign control subjects. This evidence concerns the gene SPP1 and ovarian carcinoma.